Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
125 studies found for:    thalidomide myeloma | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine + Dexamethasone + Thalidomide
2 Not yet recruiting Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Thalidomide;   Drug: Dexamethasone
3 Recruiting Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Clarithromycin;   Drug: Thalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
4 Recruiting A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD);   Drug: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab;   Drug: Daratumumab
5 Recruiting The Effects of Huang-Lian-Jie-Du-Tang(HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: HLJDT
6 Recruiting Optimising Renal Outcome in Myeloma Renal Failure
Conditions: Multiple Myeloma;   Chronic Kidney Disease
Interventions: Drug: Bortezomib;   Drug: Thalidomide;   Drug: Bendamustine;   Drug: Dexamethasone
7 Recruiting Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Thalidomide;   Drug: Lenalidomide;   Drug: Dexamethasone
8 Recruiting Study of MLN9708 Plus Oral Dexamethasone or Plus Oral Cyclophosphamide and Dexamethasone or Plus Bendamustine and Dexamethasone or Plus Oral Thalidomide and Dexamethasone Followed by Maintenance With MLN9708 in Newly Diagnosed Elderly Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Bendamustine;   Drug: Thalidomide
9 Recruiting Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
10 Recruiting Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
Conditions: Lymphoma;   Multiple Myeloma
Interventions: Drug: Tinzaparin;   Other: Blood sample
11 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
12 Recruiting Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Mitoxsnteone;   Drug: Thalidomide
13 Recruiting Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide
14 Recruiting UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
Condition: Multiple Myeloma
Intervention: Drug: MEL-CFZ-TD-PACE
15 Recruiting UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
Condition: Myeloma
Interventions: Drug: Melphalan;   Drug: Velcade;   Drug: Thalidomide;   Drug: Dexamethasone;   Drug: Cisplatin;   Drug: Adriamycin;   Drug: Cyclophosphamide;   Drug: Etoposide
16 Recruiting Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Multiple Myeloma, Refractory
Interventions: Drug: Pomalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
17 Recruiting Pomalidomide for Lenalidomide for Failures
Condition: Multiple Myeloma
Interventions: Drug: POM;   Drug: Steroids;   Drug: PLD;   Drug: CFZ;   Drug: BTZ;   Drug: CLA;   Drug: Other drugs
18 Recruiting Non-interventional Study on Salvage Auto in Relapsed Myeloma
Condition: Relapsed Multiple Myeloma
Intervention:
19 Recruiting A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Velcade;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Thalidomide;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Montelukast
20 Recruiting A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
Condition: Multiple Myeloma
Intervention: Drug: IMNOVID

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.